Novartis keeps U.K. respiratory unit after layoffs

Novartis ($NVS) delivered some upbeat news to English workers and residents this week in confirming that the Swiss drug giant plans to keep a presence at its Horsham, U.K. site that has seen hundreds of jobs cut. While it plans to offload 12 acres from the campus for redevelopment, the drugmaker wants to keep its respiratory R&D operation with a focus on asthma, chronic bronchitis, and cystic fibrosis. Plus, the company aims to invest £5 million on improvements, the local West Sussex County Times reported. Still, many jobs at the historic site, particularly those in manufacturing, aren't coming back. Article

 

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.